StreetAlpha.app
Home › Stocks › IDYA

IDEAYA Biosciences, Inc. (IDYA)

Healthcare
$25.56
▼ −2.33%
LAST CLOSE · NOV 20

IDEAYA Biosciences develops precision cancer drugs aimed at the specific genetic drivers of tumors. It last closed at $25.56 on Nov 20, down 2.33% on the day. The next earnings report for IDYA is expected around Tue, Feb 16, 2027. For the quarter ended Sep 2026, IDYA reported EPS of -$1.22 on revenue of $10.2M, with revenue down 95.1% from a year ago. Over its last 8 reports the stock moved an average of 3.8% the session after earnings. Over the last 12 months IDYA insiders bought $1.6M of stock on the open market and sold $1.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is IDYA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IDYA.

Key Stats

Last 12 months
Results
Revenue
$36.5M
−83.0% vs a year ago
Net income
−$420.0M
−1149.6% margin
EPS (diluted)
−$4.50
Free cash flow
−$349.8M
−957.4% margin
Valuation
Market cap
$2.5B
96.7M shares
P/E
–
No P/E while losing money
Price to sales
67.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$261.5M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
96.7M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $27.9M$27.9MFY2021FY2022: $50.9M$50.9MFY2022FY2023: $23.4M$23.4MFY2023FY2024: $7.0M$7.0MFY2024FY2025: $218.7M$218.7MFY2025

From IDYA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 16
Estimated date · Time not announced
Reported EPS
-$1.22
Quarter ended Sep 2026
Year ago EPS
$1.33
−191.7% on a GAAP basis
Revenue
$10.2M
−95.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.55Dec '24Mar 2025: -$0.82Mar '25Jun 2025: -$0.88Jun '25Sep 2025: $1.33Sep '25Dec 2025: -$0.94Dec '25Mar 2026: -$1.11Mar '26Jun 2026: -$1.22Jun '26Sep 2026: -$1.22Sep '26Latest -$1.22
Revenue by quarter
Dec 2024: $7.0MDec '24Sep 2025: $207.8MSep '25Dec 2025: $10.9MDec '25Mar 2026: $6.6MMar '26Jun 2026: $8.9MJun '26Sep 2026: $10.2MSep '26Latest $10.2M
How IDYA moved after its last 8 reports
Average move the session after a report ±3.8%
Nov 3, 2026Time not announced−1.0%
Aug 4, 2026Time not announced+2.0%
May 5, 2026Time not announced−0.3%
Feb 17, 2026Time not announced+1.6%
Nov 4, 2025Time not announced−2.8%
Aug 5, 2025Time not announced−3.5%
May 6, 2025Time not announced−13.3%
Feb 13, 2025Time not announced−5.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IDYAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on IDYA: 0 upgrades, 0 downgrades, 0 initiations
JPMorgan Chase & CoTarget cut
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on IDYA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IDYA

Technical Analysis

IDYA · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 21% below its 20 day and 34% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $25.46, and the nearest resistance the Pivot at $25.96.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 6.8%/day
Key levels
$42.6852 week high+67.0%
$36.02100 day average+40.9%
$34.3450 day average+34.4%
$33.70200 day average+31.8%
$30.9120 day average+20.9%
$29.97Swing high (May 27)+17.3%
$26.47Pivot R1+3.6%
$25.96Pivot+1.6%
$25.56Last close
$25.4652 week low−0.4%
$25.06Pivot S1−2.0%
Indicators
RSI (14)25.14Oversold below 30Oversold
MACD-2.12Below its signal lineBearish
Stochastic4.5Near the bottom of its rangeOversold
ADX (14)31.9Trending down
Williams %R-98.7Oversold below −80, overbought above −20Oversold
CCI (20)-204.1Oversold below −100, overbought above 100Oversold
Rate of change−18.2%Change over 10 sessionsBearish
ATR (14)$1.73Typical daily range, 6.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IDYA

What happened before

See how IDYA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IDYA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IDYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IDYAHow many large options trades hit IDYA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

IDYA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▲155 buying vs 103 selling
  • ▼Held by funds -1.4 pts
  • ▼Funds holding -4
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding281285−1.4%
In funds' top 10550.0%
Held by funds104.4%105.8%−1.4 pts
New / increased32 / 12363 / 920.0%
Reduced / sold out69 / 3487 / 35−15.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IDYA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IDYA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$1.6M1 buy · 1 insider
Sold$1.4M2 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-03 bought $1.6M2026-07 sold $382K2026-10 sold $985KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 6Yujiro S HataPresident and CEOSale plan26,338$37.41$985K
Jul 7Briseno Andres RuizChief Accounting OfficerSale plan9,550$40.01$382K
Mar 2Jeffrey SteinDirectorBuy50,000$32.96$1.6M
Every insider buy and sale for IDYA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IDYA insider trades →

From SEC Form 4 filings by IDYA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IDYA is in one of them and how their past IDYA trades turned out.

IDYA in the AI portfolios
Loading…

IDYA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IDYA in an article yet. Here's the latest on the wider market.

IDYA in the news

About IDEAYA Biosciences

IDEAYA Biosciences is a drug developer focused on cancer treatments that target specific genetic drivers of disease. Its most advanced program, darovasertib, is being studied for uveal melanoma, a rare eye cancer, and the company is also developing candidates that combine antibody drug conjugates with DNA damage response inhibitors for solid tumors. It works with partners including Pfizer and Servier, and its therapies are aimed at cancer patients. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA
Founded
2015